In response to Dr Rastegar, here is the flow diagram (Figure) showing the number of patients assessed for eligibility and the number excluded from our study1 of injectable, sustained-release naltrexone for the treatment of opioid dependence.
Comer SD, Sullivan MA, Yu E, Rothenberg JL, Kleber HD, Kampman K, Dackis C, O’Brien CP. Lack of Information in Naltrexone Study—Reply. Arch Gen Psychiatry. 2007;64(7):865. doi:10.1001/archpsyc.64.7.865-b